West Pharmaceutical Services raised its full-year revenue and adjusted earnings guidance following second-quarter results that exceeded expectations, driven by demand for biologics and biosimilars-related products. The company also highlighted continued growth in GLP-1s, which accounted for about 7% of total revenues in the first quarter, and anticipates high single-digit growth for Biologics HVP components in the second half of 2025. Despite the upgraded outlook and active buybacks, the stock has seen a 6.6% decline over the past 30 days, though it remains up 23.4% year to date. A widely followed narrative suggests the shares are undervalued, with a fair value estimate near $404 compared to a last close of $340.96, but the current price-to-earnings ratio of 42.5 times is nearly double the fair ratio of 21.9 times and above the global Life Sciences average of 37.2 times.
West Pharmaceutical Services IncRaised full-year guidance on strong Q2 driven by demand for biologics, biosimilars, and GLP-1 products.